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Abstract
Rationale: The underlying defect in the cystic fibrosis (CF) airway
leads to defective mucociliary clearance and impaired bacterial killing,
resulting in endobronchial infection and inflammation that contributes
to progressive lung disease. Little is known about the respiratory
microbiota in the early CF airway and its relationship to inflammation.
Objectives:To examine the bacterial microbiota and inflammatory
profiles in bronchoalveolar lavage fluid and oropharyngeal secretions
in infants with CF.
Methods: Infants with CF from U.S. and Australian centers were
enrolled in a prospective, observational study examining the bacterial
microbiota and inflammatory profiles of the respiratory tract. Bacterial
diversity and density (load) were measured. Lavage samples were
analyzed for inflammatory markers (interleukin 8, unbound neutrophil
elastase, and absolute neutrophil count) in the epithelial lining fluid.
Results: Thirty-two infants (mean age, 4.7 months) underwent
bronchoalveolar lavage and oropharyngeal sampling. Shannon
diversity strongly correlated between upper and lower airway
samples from a given subject, although community compositions
differed. Microbial diversity was lower in younger subjects and in
those receiving daily antistaphylococcal antibiotic prophylaxis. In
lavage samples, reduced diversity correlated with lower interleukin
8 concentration and absolute neutrophil count.
Conclusions: In infantswithCF,reducedbacterialdiversity intheupper
and lower airways was strongly associated with the use of prophylactic
antibiotics and younger age at the time of sampling; less diversity in the
lower airway correlated with lower inflammation on bronchoalveolar
lavage.Ourfindings suggestmodificationof the respiratorymicrobiome in
infants with CF may influence airway inflammation.
Keywords: cystic fibrosis; respiratory infection; bacterial
infection; pediatric lung disease inflammation; microbiota
(Received in original form February 10, 2017; accepted in final form June 15, 2017 )
*These authors contributed equally to this manuscript.
The authors were supported by National Institutes of Health grants HL116211 (T.W.F., S.D.D., and S.R.) and HL120002 (J.E.P.); National Health and Medical
Research Council awards NHMRC1043768 (S.R.), NHMRC1000896 (S.M.S.), and NHMRC APP1025550 (G.L.H.); the Children’s Discovery Institute (J.E.P.);
the Indiana Physician Scientist Award (Eli Lilly) (S.D.D.); the Thoracic Society of Australia and New Zealand Vertex Cystic Fibrosis Pediatric Clinical Fellowship
(K.B.F.); the Australian Cystic Fibrosis Research Trust Postgraduate Studentship (K.B.F.); and the Royal Children’s Hospital Cystic Fibrosis Research Trust.
The views expressed do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, nor does mention by trade names,
commercial practices, or organizations imply endorsement by the U.S. government. There are no previous publications or submissions with any overlapping
information presented in this report. J.E.P. and K.M.W. did not receive an honorarium or grant to write the manuscript.
Author Contributions: J.E.P. and K.M.W. created the study database, performed data analysis and interpretation, and prepared the manuscript; K.A.
processed and cataloged samples from the four participating sites, performed inflammatory measures, and performed data analyses; G.A.S. was involved in
study design and data interpretation; J.Q., K.B.F., M.D., and N.C. recruited subjects; J.Q., J.H., K.B.F., M.D., and N.C. coordinated study activities at their
sites and were engaged in data management; S.M.S. and G.L.H. were involved in subject recruitment and sample collection at their site and participated in
manuscript preparation; G.M. participated in subject recruitment and sample collection; S.R., S.D.D., and T.W.F. were involved in study design, study
management, subject recruitment, sample collection, data analyses and interpretation, and manuscript preparation; J.E.P. and K.M.W. composed the first
draft. The authors have reviewed and approved the content of the submission and take full responsibility for the information provided.
Correspondence and requests for reprints should be addressed to Jessica E. Pittman, M.D., Assistant Professor of Pediatrics, Division of Pediatric Allergy, Immunology, and
Pulmonary Medicine, Washington University School of Medicine, Campus Box 8116, 660 South Euclid, St. Louis, MO 63110. E-mail: pittman_j@kids.wustl.edu
This article has a data supplement, which is accessible from this issue’s table of contents online at www.atsjournals.org.
Ann Am Thorac Soc Vol 14, No 10, pp 1548–1555, Oct 2017
Copyright © 2017 by the American Thoracic Society
DOI: 10.1513/AnnalsATS.201702-121OC
Internet address: www.atsjournals.org
1548 AnnalsATS Volume 14 Number 10| October 2017
Cystic fibrosis (CF) lung disease begins during
infancy. Bacterial infection in CF airways
induces an intense neutrophilic response (1)
that contributes to airway injury (2). The cycle
of infection, neutrophilic inflammation,
oxidative stress, and overwhelmed
antiprotease defenses leads to irreversible
airway destruction. In infants and young
children with CF, lower airway infection and
inflammation have been linked to poorer
respiratory outcomes, including expiratory
airflow limitation (3) and bronchiectasis (4–6).
Historically, interventions have focused
on specific organisms associated with
progressive disease, such as Pseudomonas
aeruginosa (7, 8). However, it has become
increasingly clear that the lungs of patients
with CF have greater microbial diversity
than previously recognized. In older children
and adults, sputum and bronchoalveolar
lavage (BAL) microbiomes in CF are
relatively constant, particularly during
periods of clinical stability (9–11), and lower
bacterial diversity has been associated with
more advanced CF lung disease (12–15).
It is unknown whether reduced bacterial
diversity in the adult airway contributes to
lung disease or occurs secondary to disease
progression or its treatment.
The airway microbiome changes
during infancy (16, 17). In a recent
retrospective study, we examined the
evolution of lower airway microbiota over
time, analyzing serial BAL samples
collected more than 2 decades ago (18). The
microbiota in the CF lower airway appeared
dynamic in these retrospective samples, and
microbial diversity decreased in serial BAL
samples in association with increased
patient age. Little is known about the
evolution of the bacterial microbiota in
infancy or its relationship to early lung
disease and airway inflammation in
children with CF.
Bacterial colonization in infancy has
the potential to change the physiology and
native immunity of CF airways. The early
microbiota of the CF airway represents
a potentially modifiable factor that could
affect mucosal inflammation and disease
progression (19–21). In this manuscript, we
describe the bacterial and inflammatory
profiles in BAL fluid and oropharyngeal
secretions collected prospectively from
infants with CF seen at four U.S. and
Australian centers, building on our previous
work. We hypothesized that reduced
microbial diversity would be associated with
increased antibiotic exposure, particularly
use of prophylactic antibiotics (amoxicillin-
clavulanate), and that differences in lung
microbiota would be linked to differences in
inflammation in the lower airways.
Methods
Subjects
Infants with CF at 3 months of age were
enrolled in a prospective, observational,
multicenter study at Riley Children’s Health
(Indianapolis, Indiana), St. Louis Children’s
Hospital (St. Louis, Missouri), Princess
Margaret Hospital for Children (Perth,
Australia), and the Royal Children’s Hospital
(Melbourne, Australia). All subjects were
identified through newborn screening, with
diagnosis of CF defined as at least one
clinical feature of CF plus a documented
sweat chloride concentration greater than
60 mEq/L by quantitative pilocarpine
iontophoresis and/or compatible genotype
with two identified mutant CFTR alleles.
Families were approached consecutively.
Clinical information collected included sex,
CFTR genotype, clinical presentation,
tobacco smoke exposure, previous bacterial
infection or infections, medications, weight,
height, and vital signs. Families were
contacted weekly to inquire about
respiratory symptoms and antibiotic use
(treatment and prophylactic). BAL was
performed at 6 (62) months of age, using a
standard protocol at all sites. Interim history
and chart review was performed before
bronchoscopy, including hospitalizations,
culture data, and antibiotic use. Human
subjects committees at all sites approved this
study, informed parental consent was
obtained for all subjects, and a National
Institutes of Health-approved Observational
Safety Monitoring Board reviewed and
approved the protocol before study
initiation.
Specimens
BAL fluid and oropharyngeal swabs were
collected on the same day. A total of four
1ml/kg aliquots of sterile normal saline were
instilled into subsegmental bronchi of right
middle lobe and lingula. Routine bacterial
culture was performed on BAL fluid
according to clinical procedures at each site.
Lavage fluid and oropharyngeal swabs were
processed according to study protocols (see
the online supplement) and sent to
Washington University for inflammatory
marker and microbiome analyses.
Measurement of
Inflammatory Markers
Interleukin 8 (IL-8) concentrations and
functional activity of unopposed neutrophil
elastase were measured in BAL supernatant
(22). Values were corrected for dilution by
measuring urea concentrations in BAL
supernatant and serum (online supplement)
(23). Lavage cell counts and absolute
neutrophil counts (ANC) were determined at
each site, using established techniques (24).
Nucleic Acid Extraction
Total nucleic acid was extracted from BAL
cell pellets and oropharyngeal specimens,
using the NucliSENS easyMAG instrument
(bioMe´rieux, Inc, Marcy l’Etoile, France;
online supplement) (18).
16S rRNA Gene Quantitative
Polymerase Chain Reaction
The BactQuant assay (25) was used to
determine the number of copies of 16S
rRNA gene per milliliter of each sample as
an approximation of bacterial load (online
supplement) (18). Samples that did not
have detectable bacterial concentrations
were assigned a value of 10 copies per
microliter for analysis of bacterial load,
which was the minimum detected using a
cloned 16S rRNA gene in a standard curve
(online supplement).
16S Amplicon Sequencing
Sequencing was performed on those samples
with bacterial loads above the detection limit
of the BactQuant assay. The V1–V3 region
of the 16S rRNA gene was amplified,
sequenced on the Roche 454 GS FLX
Titanium instrument (Roche/454 Life
Sciences, Branford, CT), and processed
according to methods published by the
Human Microbiome Project (26) (online
supplement). 16S sequences were classified
using the Ribosomal Database Project
classifier (27), version 10.2, training set 10.
Sequence data were deposited into GenBank
under BioProject PRJNA311065 (18).
Sequencing Controls
As a sample control, sterile saline was
washed through bronchoscopes before
sample collection in a subset of subjects to
ensure bacterial signals in BAL samples were
distinct from background, residual bacterial
DNA from the equipment (online
supplement). Each control was run as a
separate sample, and consistently had
undetectable 16S signal by quantitative
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polymerase chain reaction (qPCR) assay
(Figure E1A). BAL samples collected from
participants directly after control washes and
using the same bronchoscope had low
detectable levels of bacteria by qPCR (Figure
E1A). For sequencing, the entire volume of
the 16S amplification reaction from each
of the controls was included in the pool of
samples. Sequence reads generated from
controls were lower in number than those
from patient samples, and patient samples
had distinct bacterial taxa and community
structures compared with controls. 16S qPCR
and sequencing were also performed on
buffers used for sample processing and PCR-
negative controls. These negative controls
had undetectable levels of bacteria in the 16S
qPCR and low numbers of sequence reads.
Statistical Analyses
Subject demographics were compared using
rank-sum testing or Fisher’s exact test, as
appropriate. The R library vegan was used
for statistical analysis of alpha diversity.
Sequence data from each sample were
adjusted (rarefied) to the number of
sequences found in the sample with the
fewest reads before calculating richness and
plotting the data. Lavage and oropharyngeal
sample data sets were treated separately,
with BAL rarefied to 1,631 sequences and
the oropharyngeal sample rarefied to 10,503
sequences. LabDSV (28) was used to
calculate beta diversity and carry out
principle coordinates analysis, and rgl (29)
was used for three-dimensional plotting. The
statistical significance of diversity and
inflammatory marker measurements
between defined groups was assessed using
rank-sum testing with continuity correction.
Spearman correlations were calculated
between measures. Differences in bacteria
between groups by antibiotic regimens were
identified using MetaStats (30); only taxa
that accounted for >0.1% of the total
classified reads were included. Associations
between alpha diversity and other factors
were examined using linear regression with
backward stepwise regression and partial F
testing (Stata; StatCorp, TX). Variables used
in the initial regression model were chosen
based on significance in bivariate analyses.
Results
Subjects
Complete data were collected on 32 infants
(16 Melbourne, 11 Indianapolis, 4 St. Louis,
1 Perth) who underwent bronchoscopy
at a mean age of 4.7 (61.8) months.
Subject demographics by continent are
described in Table 1. Australian subjects
were younger than U.S. subjects at the
time of bronchoscopy. All but one of the
Australian subjects were treated with
antistaphylococcal prophylactic antibiotics;
no U.S. subjects received prophylaxis.
U.S. subjects were more likely to receive
treatment courses of antibiotics than
Australians. Six subjects (five U.S., one
Australian) had received antibiotics
[intravenous (1), oral (4), or inhaled (1)]
during the 14 days before bronchoscopy,
including three who were still receiving
treatment at the time of the procedure.
Although most subjects were at their
clinical baseline at the time of sampling,
six children had increased respiratory
symptoms at the time of bronchoscopy
(three U.S., three Australian) (table E1).
Microbial Communities
A range of bacterial loads was seen,
particularly on BAL, even when
corrected for volume of BAL fluid
recovered and dilution (23). All
oropharyngeal samples (n = 32) had
detectable bacterial loads and underwent
nucleotide sequencing for microbiome
analysis; 22 of the BAL samples had
bacterial loads above the level of detection
and were sequenced. Analyses involving
BAL bacterial diversity were restricted to
these 22 subjects; all other analyses
included all 32 subjects. There were no
significant demographic differences
between subjects with or without detectable
bacterial loads on BAL.
Table 1. Subject demographics by continent of enrollment
Australia (N = 17) United States (N = 15)
Male 8 (47%) 3 (20%)
Caucasian/White 16 (94%) 15 (100%)
F508del homozygous 9 (53%) 8 (53%)
Age at bronchoscopy, mon 3.5 (60.9)* 6 (61.6)
Weight at bronchoscopy, kg 6.3 (61) 7 (61.3)
Lavage sequencing performed 16 (94%) 11 (73%)
Exclusively breast fed 6 (35%) 4 (27%)
Smoke exposure 2 (12%) 0
Prophylactic antibiotics 16 (94%)* 0
Treatment antibiotics 3 (18%)* 11 (73%)
No antibiotics 1 (6%) 4 (27%)
Subject demographics and characteristics by continent of enrollment, shown for all subjects (n = 32),
presented as number and percentage or mean and standard deviation. Australian subjects were
significantly younger than U.S. subjects at the time of bronchoscopy. All but one of the Australian
subjects received prophylactic antibiotics, whereas no U.S. subjects was treated with antistaphylococcal
prophylaxis (P, 0.01). U.S. subjects were more likely to receive treatment courses of antibiotics.
*P< 0.01 for difference between Australian and U.S. subjects.
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Figure 1. Correlation of Shannon diversity from lavage and oropharyngeal samples from individual
subjects. Spearman correlation = 0.8; P, 0.0001.
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A variety of bacterial communities was
detected in both BAL and oropharyngeal
samples (Figures E1 and E2). Of 195 distinct
taxa identified from the 22 subjects with
both oropharyngeal and BAL sequencing
data, 102 (52%) were identified in both
oropharyngeal and BAL samples; 53 (27%)
were identified only in oropharyngeal
samples, and 40 (21%) in BAL only. Relative
abundance was higher for taxa identified in
both oropharyngeal and BAL samples
compared with oropharynx or BAL only
(P, 0.01).
Several genera previously reported as
possible reagent contaminants (31) were
found in some samples, including
Bradyrhizobium and Rhizobium (Figures
E2 and E3). Bradyrhizobium was also
detected in several negative controls;
Rhizobium was not. All potential
contaminant taxa were present at
exceptionally low levels, whereas the
dominant signals defining bacterial
communities were from genera consistent
with the human respiratory tract.
Agreement between Lavage and
Oropharyngeal Sample Diversity
Lavage and oropharyngeal communities had
similar diversity. Principle coordinates
analysis from subjects with sequence data
from both sample types showed clustering of
BAL and oropharyngeal communities.
Importantly, both sample types clustered
distinctly from negative control samples
(Figure E1C). Alpha diversity (Shannon
index) showed strong intrasubject
correlation between oropharyngeal and
lavage samples (Figure 1). Intrasubject
agreement between oropharyngeal and
lavage sample bacterial loads was low
(R = 0.02).
When considering specific taxa found
in the BAL and oropharyngeal communities
(Figure E3), Streptococcus spp. largely
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Figure 2. Shannon diversity differs with exposure to daily prophylactic antibiotics in lavage fluid and oropharyngeal swabs. Subjects are divided by
antibiotic exposure, with subjects who received prophylactic antibiotics designated in red and those who did not in blue. Shannon diversity in (A) lavage and
(B) oropharyngeal samples of subjects who received no antibiotics (labeled N), only prophylactic antibiotics (labeled P), only intermittent antibiotics for
treatment of illness or eradication protocol (labeled T), and those who received both daily prophylactic antibiotics and courses of antibiotics for treatment of
illness or eradication (labeled TP). Significant differences were seen between N and P (P, 0.01), and N and TP (P, 0.01). (C) Composite bacterial
communities in lavage (BAL) and oropharyngeal (OP) samples for all subjects segregated by exposure to daily prophylactic antibiotics (N and P represent no
prophylaxis and prophylaxis, respectively), with each row representing a distinct bacterial taxon and relative abundance reflected by color intensity.
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dominated both sample types. Intrasubject
agreement between oropharyngeal and
BAL samples for individual taxa varied
widely, but agreement was stronger for the
10 taxa most abundant in the entire study
population for either BAL or oropharyngeal
sampling, which made up 88% and 92%
of the total BAL and oropharyngeal
sequences, respectively. Frequently, the
major components of the BAL samples
consisted of the same genera found in the
oropharynx (Table E2).
Comparisons between Conventional
Bacterial Culture and Sequencing of
Lavage Samples
Using standard clinical laboratory microbial
culture techniques, 9 of 32 BAL samples
(28%) reported no growth, 13 yielded
only normal oropharyngeal flora, and 10
produced oropharyngeal flora with growth
additional bacterial species, including
methicillin-sensitive and methicillin-
resistant Staphylococcus aureus,
Pseudomonas aeruginosa, Haemophilus
influenzae, Stenotrophomonas maltophilia,
Moraxella catarrhalis, Escherichia coli,
Klebsiella pneumoniae, and Morganella
morganii. Nine of these 10 samples had
adequate bacterial load for sequencing,
with identification of all but two taxa
(Pseudomonas and Klebsiella) at the
genus level, though some had few reads.
Conventional culture of the 10 BAL
samples with bacterial load below the level
of qPCR yielded a specific pathogen
(methicillin-sensitive Staphylococcus
aureus) in a single subject; six had no
significant growth, and three were reported
as normal oropharyngeal flora.
Association of Bacterial Load and
Diversity, Inflammation, and
Antibiotic Prophylaxis
Using bivariate analysis, subjects receiving
daily amoxicillin-clavulanate therapy as
antistaphylococcal prophylaxis had slightly
lower bacterial loads in oropharyngeal, but
not BAL samples than those who did not
receive prophylaxis (Figure E4). Use of
antibiotic prophylaxis, however, was
strongly associated with lower Shannon
diversity in both BAL and oropharyngeal
samples (Figure 2). There was not a
significant difference in diversity between
subjects with intermittent exposure to
antibiotics (e.g., for treatment of
exacerbations or nonrespiratory
infections) and subjects who never
received antibiotic therapy, nor was
there a difference in diversity in subjects
who received only prophylactic antibiotics
compared with those who received both
prophylaxis and intermittent treatment
courses (Figure 2). Other measures of
alpha diversity yielded similar results,
including measures of richness, Simpson
diversity index, and Pielou evenness
(Figure E5). Lower diversity of
oropharyngeal and BAL samples also
correlated with younger age and Australian
subjects.
When q-value cutoffs (,0.1) were
applied, there was no association between
presence of specific taxa and prophylactic
antibiotic usage, except Fusobacterium,
which was present at very low abundances
and appeared more common in infants
who did not received prophylactic
antibiotics (q = 0.03).
Lower lavage ANC was associated
with both lower Shannon diversity on BAL
and use of prophylactic antibiotics. Lower
lavage IL-8 was found in BAL samples that
had lower Shannon diversity, but not
antibiotic prophylaxis (Figure 3). There was
no correlation between bacterial load and
BAL inflammatory measures (Figure E6).
Three subjects had detectable free
neutrophil elastase in BAL fluid; none were
found in the prophylactic antibiotic cohort
(P, 0.01). Presence of neutrophil elastase
was significantly associated with respiratory
symptoms at bronchoscopy (P = 0.006),
but ANC and IL-8 concentrations were not.
Subject characteristics were next
compared between prophylaxis and no
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Figure 3. Association of inflammatory markers with prophylactic antibiotic use and bacterial diversity.
In all panels, subjects receiving antibiotic prophylaxis (P) are shown in red circles, whereas those not
receiving prophylaxis (N ) are in blue. (A) Significantly lower absolute neutrophil counts (ANC) were
found in the group treated with prophylactic antibiotics (P, 0.01). (B) Correlation between absolute
neutrophil count and Shannon diversity in lavage samples (R = 0.82; P, 0.01). (C ) There was no
difference in interleukin 8 (IL-8) levels between the two groups (P = 0.07). (D) Correlation between IL-8
lavage concentration and Shannon diversity in lavage samples (R = 0.44; P = 0.04). ELF = epithelial
lining fluid.
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prophylaxis groups. There were no
differences in sex or CFTR genotype
between the two groups. Subjects in the
prophylaxis group were all Australian, were
younger at the time of sampling, and were
less likely to have received a treatment
course of antibiotics (Table 2).
The association between bacterial
diversity and subject characteristics,
antibiotic use, and inflammation was
examined using linear regression analyses,
performed separately for oropharyngeal and
BAL samples. Variables in the initial model
were chosen based on significance in
bivariate analyses, and included bacterial
diversity and load, prophylactic antibiotic
use, treatment antibiotic use, age at
bronchoscopy, continent, BAL inflammatory
markers (ANC and IL-8), symptoms at time
of bronchoscopy, and volume of fluid
collected (BAL analysis only). Treatment
antibiotic use was modeled as a categorical
variable (treatment antibiotics within
14 days of bronchoscopy, .14 days from
bronchoscopy, or never). Only use of
prophylactic antibiotics and younger age
at bronchoscopy showed significant
associations with lower bacterial diversity in
both upper and lower respiratory tract
samples. Bacterial load showed a slight
association with diversity in oropharyngeal
samples, but was not associated with
diversity in BAL samples (Table 3).
Discussion
As part of a novel, international
collaboration comprehensively examining
the earliest origins of CF lung disease, we
have identified associations between
bacterial diversity of the respiratory tract
microbiome and antibiotic exposure in
young infants with CF. Lower bacterial
diversity correlated with prophylactic
antibiotic use and younger age at sampling.
We also found a strong intrasubject
correlation between respiratory microbial
diversity in BAL and oropharyngeal
samples, particularly for the presence of
more abundant taxa, although exact
community structures often differed.
Our understanding of the complex
polymicrobial community in the lower
airways of patients with CF has begun to
alter our thinking on the role of colonizing
and infecting bacteria in CF airways.
Culture-independent methods for
quantitative profiling of bacterial
populations have opened a new era in
investigation (32), demonstrating that
respiratory tract microbial profiles can
change with age (20) and antibiotic use
(33), and evolve in young children (16).
The upper and lower respiratory tract
samples we have collected from infants
across four centers in two continents
provides a unique opportunity to
understand the diversity and complexity
of the airway microbiota in infants with
CF, and has yielded insights into factors
that may influence airway bacterial
communities in early life.
We recently reported an association
between lower diversity in BAL samples
and increasing age in a historical cohort of
young Australian children with CF sampled
before routine use of antistaphylococcal
prophylaxis (18). We applied similar
processing and sequencing approaches to
examine airway bacterial diversity in
infants with CF in the era of routine
prophylaxis. Our findings suggest that
administration of prophylactic antibiotics
decrease bacterial diversity of the CF airway
in infancy. Interestingly, prophylactic
antibiotic use was not associated with lower
bacterial load in BAL samples (although all
bacterial loads detected were relatively low).
Intermittent administration of treatment
courses of antibiotics was not associated
with differences in microbial diversity of
the lower airways, though our small
sample size and variability of timing of
antibiotics in relation to sampling limited
our ability to fully explore this relationship.
We found that bacterial diversity in
oropharyngeal secretions strongly correlated
with lower airway samples, which is in
agreement with previous studies (32).
The most abundant taxa found were
represented in both samples, but the exact
community compositions differed.
Strong intrasubject correlation between
oropharyngeal and lavage sample
diversity, combined with similar findings
of the association of age and prophylactic
antibiotic use with diversity on oropharyngeal
and lavage sampling, strengthens our
findings, as each type of sampling has
different limitations. Further, these
observations could influence sampling
modality choice in future studies
investigating airway diversity in infants,
as oropharyngeal secretions are more
easily obtainable than BAL fluid and may
represent a more consistent means of
Table 2. Subject characteristics by administration of prophylactic antibiotics
All Subjects (N = 32) Subjects with Lavage Sequencing Data (N = 22)
No Prophylaxis
(N = 16)
Antibiotic Prophylaxis
(N = 16)
No Prophylaxis
(N = 10)
Antibiotic Prophylaxis
(N = 12)
Male 3 (18%) 8 (50%) 3 (30%) 5 (42%)
Caucasian/White 16 (100%) 15 (94%) 10 (100%) 12 (100%)
F508del homozygous 9 (56%) 8 (50%) 7 (70%) 7 (58%)
U.S. subject* 15 (94%) 0 9 (90%) 0
Age at bronchoscopy, mo* 5.8 (61.7) 3.5 (60.9) 5.8 (61.8) 3.5 (61)
Weight at bronchoscopy, kg 6.9 (61.3) 6.3 (60.9) 7.2 (61.2) 6.2 (60.9)
Exclusively breast-fed 4 (25%) 6 (37%) 3 (30%) 3 (25%)
Smoke exposure 0 2 (12%) 0 2 (17%)
Treatment antibiotics* 11 (69%) 3 (18%) 6 (60%) 2 (17%)
No antibiotics 5 (31%) 4 (40%)
Subject characteristics by administration of prophylactic antibiotics (amoxicillin-clavulanic acid) for all subjects and the subgroup with lavage sequencing
data. No significant differences were seen between the groups with and without lavage sequencing data.
*P, 0.05 comparing no prophylaxis and prophylaxis groups both among all subjects and only those with lavage sequencing data.
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surveying bacterial diversity of the
respiratory tract in studies of children
with CF.
This study has several limitations.
As it is an observational study, participants
were not randomly assigned to receive
prophylactic antibiotics, and thus this
intervention was strongly tied to geography.
Several subjects had respiratory symptoms
and/or were treated with antibiotics at the
time of bronchoscopy, which could influence
diversity and inflammatory measures.
Australian subjects were, as a whole, studied
at a younger age than their American
counterparts. Differences seen in microbial
diversity could also be influenced by
differences in the local environment, age, or
both. However, historic samples in children
younger than 1 year of age from the
Royal Children’s Hospital, collected before
initiation of antistaphylococcal prophylaxis,
had markedly higher diversity indices
than our current samples from the same
institution (18), suggesting geography is not
the sole contributor to differences noted
within our study populations.
Compliance with antibiotic regimens
was not monitored; thus, it is possible some
subjects in the prophylaxis group did not
receive antibiotics as prescribed. The timing
of treatment courses of antibiotics and
sampling was not uniform, and could have
an effect on observed associations. Small
sample size also limited our ability to
explore associations between specific taxa in
BAL fluid and lung inflammation. Although
low total BAL bacterial loads may
have limited our ability to identify
associations of load and inflammation, the
microbial communities and bacterial
densities observed were significantly
different between subject samples and
methodological controls, making it unlikely
that our findings were spurious, related
to background signal, or contamination.
We were unable to speciate bacteria
identified, and thus cannot comment on
pathogenicity of specific organisms.
Australian subjects had lower volumes
of BAL samples available for analysis,
related to yields from small infants, which
could have had an effect on the detection of
taxa present at low levels. Despite these
limitations, BAL volume was not associated
with bacterial load or with bacterial diversity
in the final regression model. The strong
correlation between oropharyngeal and
BAL diversity, as well as the association of
both oropharyngeal and BAL diversity
with prophylactic antibiotic use, suggests
differences in diversity are not simply
related to differences in lavage sample
volume or technique. We believe
the uniqueness of our sample set of
prospectively collected lavage samples from
infants and the counterarguments outlined
here more than balance the limitations
of this study. In summary, we have shown in
a cohort of infants with CF that microbial
diversity of the upper and lower respiratory
tract is associated with administration of
prophylactic antibiotics, and reduced
diversity in the lower airways is associated
with less inflammation in the lower airways.
We continue to follow these infants, which
will allow us to determine whether these
findings persist. By recognizing the earliest
origins of CF lung disease, we expect to
better understand pathogenesis and identify
therapeutic targets or interventions that
could alter its trajectory (19). n
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